Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

ONCO

O

Onconetix, Inc. (ONCO)

NCM – Real Time Price. Currency in USD

1.94

-1.28 (-39.75%)

At close: Mar 27, 2026, 4:00 PM EDT

1.51

-0.43 (-22.16%)

After-hours: Mar 27, 2026, 7:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration

Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration

Realbotix Humanoid Robot — Ericsson's First Enterprise Robotics Client — Featured as Live Connected Endpoint in Pre-Standard 6G Over-the-Air Trial at Ericsson's U.S. Headquarters; Onconetix Has Entered into a Definitive Agreement to Acquire Realbotix

Onconetix, Inc. Announces 1-for-5 Reverse Stock Split

Onconetix, Inc. Announces 1-for-5 Reverse Stock Split

CINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that its Board of Directors (the “Board of Directors” or “Board”) has approved a 1-for-5 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on March 25, 2026.

Onconetix, Inc. (ONCO) M&A Call Transcript

Onconetix, Inc. (ONCO) M&A Call Transcript

Onconetix, Inc. (ONCO) M&A Call Transcript

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company

A leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech Inc), and Realbotix LLC. (“Realbotix”), a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT) (“Realbotix Parent “), today announced the signing of a definitive share exchange agreement pursuant to which Onconetix will acquire 100% of the issued and outstanding equity interests of Realbotix in an all-stock transaction.

Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer

Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer

LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Parent Company”), a leader in AI-powered humanoid robots, announces it has entered into a definitive agreement with Onconetix, Inc (NASDAQ: ONCO) (“ONCO”), pursuant to which ONCO will acquire 100% of Realbotix, LLC (“RealLLC” or the “Subsidiary”), a wholly owned subsidiary of Realbotix in an all-stock transaction. RealLLC is a Nevada based wholly owned subsidiary of Realbotix. RealLLC.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Onconetix, Inc. (NASDAQ: ONCO ) related to its merger with Ocuvex Therapeutics, Inc. Upon completion of the proposed transaction, each share of Ocuvex will be exchanged for a number of Onconetix shares based on a defined exchange ratio, resulting in Ocuvex shareholders owning approximately 90% of the combined company and Onconetix shareholders owning approximately 10%. Is it a fair deal?

ONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to Shareholders

ONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Onconetix, Inc. (NASDAQ: ONCO) and Ocuvex Therapeutics, Inc. is fair to Onconetix shareholders. Upon completion of the proposed transaction, Onconetix shareholders will own 10% of the combined company. Halper Sadeh encourages Onconetix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@hal.

Videos

No Data

There is no data to display